Update: The deadline has been extended to April 30, 2018.
A study to look at a new investigational immunotherapy for peanut allergy is presently underway at Inflamax Research in Mississauga, Ontario.
The research team is seeking youth aged 12-17 with a peanut allergy, with no history of anaphylaxis, to participate in this study. Please see their call for participants below for more details. If your child is interested in participating, we encourage you to contact the research team directly to learn more about potential risks and benefits of this study, and to also speak with your child’s physician.
From the research team
Currently, there is no effective treatment for peanut allergy other than avoidance of peanut allergens. Our research team at Inflamax Research Ltd., led by Dr. Peter Couroux is looking at the safety and tolerability of an immunotherapy injection just under the skin with an investigational modified peanut extract in adolescents 12 to 17 years of age.
To be eligible to participate, you must meet the following requirements:
- 12 to 17 years of age (parent/guardian must sign a consent form)
- Diagnosis: Your child must have received a peanut allergy diagnosis from an allergist, family doctor, or pediatrician. Participants should not have a history of anaphylaxis.
- Your child must be able to travel to our Mississauga clinic for weekly visits that last 5 hours in duration.
How to participate
Participation will involve the following:
- Step 1: Passing a telephone questionnaire (10 minute call with a recruitment coordinator)
- Step 2: Attending a screening visit at the Inflamax Research clinic in Mississauga, Ontario
- Step 3: Once your child is deemed eligible for the study, there will be 15 visits to the Inflamax Research clinic to complete the immunotherapy dosing schedule (each visit would last approximately 5 hours)
- Step 4: Participating in a few follow-up phone calls upon completing the dosing schedule
The study should take approximately 4 months to complete and each clinic visit will last around 5 hours. Participants who successfully complete the study will receive a maximum compensation of $4,250 Canadian.
Participation in this study is entirely voluntary. You may refuse to participate or you may discontinue your participation at any time without explanation. All information obtained during this study will be kept strictly confidential. The research data will be available only to the research team. This study has been approved by the IRB Services, an independent Research Ethics Board.
Register for the study
To register for this study, please click on this link: www.SneezeToronto.com and complete the “study participation inquiry form” or call into the recruitment centre. Registration will be open until April 30, 2018.
If you have any questions about this study, please contact Francesca Palmieri at email@example.com or 905-282-1808.
More information on the study can be found on the ClinicalTrials.gov site: https://clinicaltrials.gov/ct2/show/NCT02991885?term=couroux&cond=Peanut+Allergy&rank=1Tags: call for participation, immunotherapy study, peanut allergy